Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03861273 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B
A Phase 3 study of Hemophilia B, sponsored by Pfizer.
- Active
- Registry status
- Phase 3
- Development phase
- 51
- Enrollment target
- 20
- Study locations
NCT03861273 is a Phase 3 study of Hemophilia B that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 51 participants, below the 94-participant average among 20 other Hemophilia B trials with a reported enrollment target (46% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT03861273, a Phase 3 study of Hemophilia B, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 51 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy and safety of PF-06838435 (a gene therapy drug) in adult male participants with moderately severe to severe hemophilia B (participants that have a Factor IX circulating activity of 2% or less). The gene therapy is designed to introduce genetic material into cells to compensate for missing or non-functioning Factor IX. Eligible study participants will have completed a minimum 6 months of routine Factor IX prophylaxis therapy during the lead in study (C0371004). Participants will be dosed once (intravenously) and will be evaluated over the course of 6 years. The main objective of the study will evaluate the annualized bleeding rate \[ABR\] for participants treated with gene therapy versus standard of care (SOC) therapy (FIX prophylaxis replacement regimen).
Conditions Studied
Interventions
- BIOLOGICAL PF-06838435/ fidanacogene elaparvovec
Study Locations (20)
California
- UCSF IDS Pharmacy - San Francisco
- University of California, San Francisco - Clinical Research Center - San Francisco
- University of California, San Francisco - Outpatient Hematology Clinic - San Francisco
- The Regents of the University of California, San Francisco campus - San Francisco
Indiana
- Indiana Hemophilia & Thrombosis Center, Inc. - Indianapolis
- Indiana Hemophilia and Thrombosis Center, Inc - Indianapolis
- Innovative Hematology, Inc. - Indianapolis
- St. Vincent Hospital & Health Care Center, Inc. - Indianapolis
Pennsylvania
- Center for Human Phenomic Science - Philadelphia
- Investigational Drug Service - Philadelphia
- Penn Blood Disorder Center - Philadelphia
- The Trustees of the University of Pennsylvania, Office of Clinical Research- Legal - Philadelphia
Colorado
- Hemophilia and Thrombosis Center at the University of Colorado Anschutz Medical Campus - Aurora
- Regents of the University of Colorado University of Colorado Denver, Office of Grants and Contracts - Aurora
Mississippi
- Madison Radiological Group - Madison
- Mississippi Center for Advanced Medicine - Madison
New South Wales
- Royal Prince Alfred Hospital - Camperdown
South Australia
- Royal Adelaide Hospital - Adelaide
Victoria
- The Alfred Hospital - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2019-07-29 |
| Est. Completion | 2031-02-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03861273
The ClinicalTrials.gov registry entry for NCT03861273 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 94-participant average among 20 other Hemophilia B trials with a reported enrollment target (46% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hemophilia B appearing as the primary indexed condition, and to 1 intervention - of which PF-06838435/ fidanacogene elaparvovec is the first listed.
NCT03861273 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Indiana, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03861273 about?
NCT03861273 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B". This study will evaluate the efficacy and safety of PF-06838435 (a gene therapy drug) in adult male participants with moderately severe to severe hemophilia B (participants that have a Factor IX circulating activity of 2% or less). The gene therapy is designed to introduce genetic material into cell...
What is the current status of trial NCT03861273?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 51 participants. The study started on 2019-07-29. Estimated completion is 2031-02-25.
What conditions does trial NCT03861273 study?
This clinical trial studies the following conditions: Hemophilia B.
What interventions are being tested in trial NCT03861273?
The interventions under investigation include: PF-06838435/ fidanacogene elaparvovec (BIOLOGICAL).
Who is sponsoring clinical trial NCT03861273?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03861273 being conducted?
This trial has 20 study locations across California, Colorado, Indiana, Mississippi, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia B
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
RECRUITING · Phase 3
-
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RECRUITING · Phase 3
-
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
RECRUITING · Phase 3
-
Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
RECRUITING · Phase 3
-
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
RECRUITING · Phase 3
-
A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.